LIGAND PHARMACEUTICALS INC·4

Jun 9, 7:41 PM ET

Sabba Stephen L 4

4 · LIGAND PHARMACEUTICALS INC · Filed Jun 9, 2026

Research Summary

AI-generated summary of this filing

Updated

Ligand Pharmaceuticals (LGND) Director Stephen Sabba Receives RSU Award

What Happened
Stephen L. Sabba, a Director of Ligand Pharmaceuticals (LGND), received equity awards on June 5, 2026: 836 restricted stock units (RSUs) and an additional 2,938 derivative awards (RSU-type), each granted at $0.00. Total units granted = 3,774. These were board-approved grants (transaction code A) and involve no cash outlay by the insider at grant.

Key Details

  • Transaction date: 2026-06-05; Filing date (Form 4): 2026-06-09 (timely filed within required business days).
  • Price: $0.00 per share (standard for RSU grants); total cash paid = $0.
  • Vesting: Awards fully vest on the earlier of (A) the date of the next annual meeting of stockholders following the grant or (B) the first anniversary of the grant (per footnotes).
  • Nature: 836 RSUs (explicit RSUs); 2,938 reported as derivative/RSU-type awards — contingent rights to receive common stock on vesting.
  • Shares owned after transaction: Not specified in the Form 4 filing.
  • No 10b5-1 plan, tax-withholding sale, or sale/exercise reported in this filing.

Context
This is a standard board equity grant to a director, not a market purchase or sale. RSU awards are common compensation and become actual shares only if/when they vest; they do not by themselves indicate buying or selling sentiment.

Insider Transaction Report

Form 4
Period: 2026-06-05
Transactions
  • Award

    Common Stock

    [F1]
    2026-06-05+83633,629 total
  • Award

    Non-Qualified Stock Option (right to buy)

    [F2]
    2026-06-05+2,9382,938 total
    Exercise: $237.00Exp: 2036-06-05Common Stock (2,938 underlying)
Footnotes (2)
  • [F1]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
  • [F2]Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Signature
/s/ Stephen L. Sabba|2026-06-09

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT